Progress in the Development of Volatile Exhaled Breath Signatures of Lung Cancer

Abstract

The colorimetric sensor array signature of exhaled breath volatile organic compounds was capable of distinguishing patients with lung cancer from clinically relevant control subjects in a discovery level trial. The incorporation of clinical phenotypes into the further development of this biomarker may optimize its accuracy.